JP2012511026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012511026A5 JP2012511026A5 JP2011539761A JP2011539761A JP2012511026A5 JP 2012511026 A5 JP2012511026 A5 JP 2012511026A5 JP 2011539761 A JP2011539761 A JP 2011539761A JP 2011539761 A JP2011539761 A JP 2011539761A JP 2012511026 A5 JP2012511026 A5 JP 2012511026A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- lipid
- fragment
- amino acid
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002632 lipids Chemical class 0.000 claims 29
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 21
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 230000000975 bioactive effect Effects 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 11
- 239000003446 ligand Substances 0.000 claims 10
- 239000013078 crystal Substances 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 7
- 229940024606 amino acid Drugs 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 238000000126 in silico method Methods 0.000 claims 2
- 238000000302 molecular modelling Methods 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000007670 refining Methods 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12031808P | 2008-12-05 | 2008-12-05 | |
| US61/120,318 | 2008-12-05 | ||
| US15589509P | 2009-02-26 | 2009-02-26 | |
| US61/155,895 | 2009-02-26 | ||
| US23125809P | 2009-08-04 | 2009-08-04 | |
| US61/231,258 | 2009-08-04 | ||
| PCT/US2009/066862 WO2010065921A2 (en) | 2008-12-05 | 2009-12-04 | Antibody design using anti-lipid antibody crystal structures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012511026A JP2012511026A (ja) | 2012-05-17 |
| JP2012511026A5 true JP2012511026A5 (https=) | 2012-06-28 |
Family
ID=42233904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011539761A Pending JP2012511026A (ja) | 2008-12-05 | 2009-12-04 | 抗脂抗体結晶構造を用いた抗体設計 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110044990A1 (https=) |
| EP (1) | EP2374001A4 (https=) |
| JP (1) | JP2012511026A (https=) |
| KR (1) | KR20110097923A (https=) |
| CN (1) | CN102573905A (https=) |
| AU (1) | AU2009322185A1 (https=) |
| CA (1) | CA2745436A1 (https=) |
| IL (1) | IL213358A0 (https=) |
| WO (1) | WO2010065921A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011153416A2 (en) * | 2010-06-04 | 2011-12-08 | Lpath, Inc. | Novel anti-s1p antibody variants of lt1009 |
| ITRM20100441A1 (it) * | 2010-08-05 | 2012-02-06 | Michele Pitaro | Procedimento per la produzione di anticorpi monoclonali anti-idiotipo ad uso diagnostico e/o terapeutico |
| KR102165384B1 (ko) * | 2012-08-07 | 2020-10-16 | 메사추세츠 인스티튜트 오브 테크놀로지 | 항-뎅기 바이러스 항체 및 이들의 용도 |
| AU2015217149B2 (en) | 2014-02-11 | 2020-09-10 | Massachusetts Institute Of Technology | Novel full spectrum anti-dengue antibody |
| KR20170076756A (ko) | 2014-10-30 | 2017-07-04 | 텍스타일-베이스드 딜리버리, 인코포레이티드 | 전달 시스템 |
| CN110698560B (zh) * | 2015-12-24 | 2021-11-26 | 凯惠科技发展(上海)有限公司 | 一种tpbg抗体及其制备方法、其偶联物和应用 |
| US20190214108A1 (en) * | 2016-09-16 | 2019-07-11 | Osaka University | Immunological entity clustering software |
| CN117050176A (zh) | 2017-07-31 | 2023-11-14 | 豪夫迈·罗氏有限公司 | 基于三维结构的人源化方法 |
| CN107480360B (zh) * | 2017-08-03 | 2020-04-24 | 中北大学 | 光束细分和相界面漫反射的激光烧熔的数值计算方法 |
| CN109837250B (zh) * | 2019-01-15 | 2021-10-12 | 中国农业科学院兰州兽医研究所 | 羔羊睾丸支持细胞永生化细胞系及其建立方法和应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) * | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| WO1988007089A1 (en) * | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20040049014A1 (en) * | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5229275A (en) * | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| EP1400536A1 (en) * | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5932448A (en) * | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5777085A (en) * | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| ATE244763T1 (de) * | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
| US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6129914A (en) * | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US5573905A (en) * | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| GB9223377D0 (en) * | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| US6210671B1 (en) * | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
| US5534615A (en) * | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) * | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| ES2375931T3 (es) * | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| WO1999045959A1 (en) * | 1998-03-13 | 1999-09-16 | Dana-Farber Cancer Institute, Inc. | Humanized antibody and uses thereof |
| JP2002531466A (ja) * | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス， インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
| CA2432978C (en) * | 2000-12-22 | 2012-08-28 | Medlyte, Inc. | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US7678386B2 (en) * | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
| US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| WO2007038392A2 (en) * | 2005-09-23 | 2007-04-05 | Walter Reed Army Institute Of Research (Wrair) | Antibodies with simultaneous subsite specificities to protein and lipid epitopes |
| US20080213274A1 (en) * | 2005-10-28 | 2008-09-04 | Sabbadini Roger A | Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye |
| US8796429B2 (en) * | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
| US20080138334A1 (en) * | 2006-05-31 | 2008-06-12 | Sabbadini Roger A | Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same |
| US9274129B2 (en) * | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
| EP2083862A4 (en) * | 2006-10-27 | 2012-09-19 | Lpath Inc | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS |
| BRPI0718118A2 (pt) * | 2006-10-27 | 2017-05-30 | Lpath Inc | composições e métodos para ligação de sphingosine-1-fosfato |
-
2009
- 2009-12-04 WO PCT/US2009/066862 patent/WO2010065921A2/en not_active Ceased
- 2009-12-04 AU AU2009322185A patent/AU2009322185A1/en not_active Abandoned
- 2009-12-04 EP EP09831241A patent/EP2374001A4/en not_active Withdrawn
- 2009-12-04 KR KR1020117015390A patent/KR20110097923A/ko not_active Withdrawn
- 2009-12-04 US US12/631,784 patent/US20110044990A1/en not_active Abandoned
- 2009-12-04 CA CA2745436A patent/CA2745436A1/en not_active Abandoned
- 2009-12-04 JP JP2011539761A patent/JP2012511026A/ja active Pending
- 2009-12-04 CN CN2009801562855A patent/CN102573905A/zh active Pending
-
2011
- 2011-06-05 IL IL213358A patent/IL213358A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012511026A5 (https=) | ||
| JP7668617B2 (ja) | ｐＨ依存的抗体の調製方法 | |
| JP2018535670A5 (https=) | ||
| RU2008126948A (ru) | Связывающие полипептиды и их применения | |
| JP2017503787A (ja) | モノクローナル抗ｔｋ１抗体 | |
| RU2015129813A (ru) | Антитела, которые связываются с лигандом запрограммированной клеточной смерти 1 (pd-l1) | |
| NZ602621A (en) | Antibodies against csf-1r | |
| JP2007530068A5 (https=) | ||
| JP2009517057A5 (https=) | ||
| JP2020537520A5 (https=) | ||
| JP2007501011A5 (https=) | ||
| JP7432502B2 (ja) | 分析目的のための多価単一または二重特異性組換え抗体 | |
| Nahshol et al. | Parallel kinetic analysis and affinity determination of hundreds of monoclonal antibodies using the ProteOn XPR36 | |
| JP2025111457A5 (https=) | ||
| JP2018520127A5 (https=) | ||
| CN113677701B (zh) | 产生亲合结合多特异性抗体的方法 | |
| CN114555642A (zh) | 提升抗体对于抗原的亲和性的方法及其利用 | |
| Murphy et al. | Enhancing recombinant antibody performance by optimally engineering its format | |
| US20240400672A1 (en) | Novel monoclonal antibodies directed against l-thyroxine and diagnostic uses thereof | |
| US20110275857A1 (en) | Antibody-Guided Fragment Growth | |
| JP2018535403A (ja) | 黒色腫の診断マーカーとしてのｇｄｆ−１５ | |
| JP7691234B2 (ja) | 抗体の抗原に対する親和性を向上させる方法及びその利用 | |
| US10414818B2 (en) | Thermus thermophilus SlyD FKBP domain specific antibodies | |
| JPWO2020102387A5 (https=) | ||
| CN115561456B (zh) | 体外定量b肝病毒大表面蛋白的套组以及用于处理肝病的生物指标组及单株抗体组 |